In addition, the combination markedly inhibited cell migration in both ovarian cancer cell lines.<h4>Conclusions</h4>This preclinical provides evidence that combined PARP1 inhibition and curcumin treatment can exert synergistic antitumor effects in ovarian cancer models, including relatively platinum-resistant disease, through the coordinated suppression of proliferation, induction of regulated apoptosis, and inhibition of migration. Here, PARP1 is linked to ovarian carcinoma.